Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 130

Sort by

Sort Order Select

Journal Articles

Persistent Thrombocytopenia and Neutropenia Are Associated with Increased Mortality in Patients Treated with Anti-BCMA CAR T Cells for Relapsed/Refractory Multiple Myeloma

Blood (2024) 144 (Supplement 1): 7095.

https://doi.org/10.1182/blood-2024-202101

Published: 2024

Journal Articles

CT-Based Muscle Quality and Visceral Obesity Prior to Allogeneic Hematopoietic Stem Cell Transplantation Is of Prognostic Relevance in Patients with Acute Myeloid Leukemia

Jule Ussmann, Clara Wall, Lara Bischof, Jacob Jendro, Dominic Brauer, Donata Backhaus, Klaus H Metzeler, Marco Herling, Carmen Herling, Vladan Vucinic, Georg-Nikolaus Franke, Maximilian Merz, Timm Denecke, Uwe Platzbecker, Sebastian Schwind, Hans-Jonas Meyer, Madlen Jentzsch

Blood (2024) 144 (Supplement 1): 2158.

https://doi.org/10.1182/blood-2024-199943

Published: 2024

Journal Articles

The Prognostic Impact of Myelodysplasia-Related Gene Mutations in Acute Myeloid Leukemia with FLT3 -ITD Mutations

Blood (2024) 144 (Supplement 1): 844.

https://doi.org/10.1182/blood-2024-202362

Published: 2024

Journal Articles

Trial in Progress: A Randomized-Controlled Phase 2 Study Evaluating Venetoclax Plus Azacitidine Versus Intensive Chemotherapy in Adult Patients with Newly Diagnosed, NPM1 -Mutated AML - the SAL/AMLCG Vincent Trial

Blood (2024) 144 (Supplement 1): 1527.1.

https://doi.org/10.1182/blood-2024-198164

Published: 2024

Journal Articles

Prognostic Value of Baseline and Early Response FDG-PET/CT Combined with Cellular Dynamics in Patients with Refractory and Relapsed Mantle Cell Lymphoma (MCL) Undergoing Chimeric Antigen Receptor (CAR)-T Cell Therapy

Blood (2024) 144 (Supplement 1): 6343.

https://doi.org/10.1182/blood-2024-206686

Published: 2024

Journal Articles

Serially Transplantable, Genetically Modified Patient Derived Xenograft Models of Acute Myeloid Leukemia Represent Primary Patients' Cells and Enable Reliable and Reproducible Preclinical Therapy Trials

Blood (2024) 144 (Supplement 1): 6085.

https://doi.org/10.1182/blood-2024-198652

Published: 2024

Journal Articles

Preliminary Safety and Efficacy of Luspatercept Initiated at Maximum Approved Dose in Patients with Transfusion Dependent Anemia Due to Very Low, Low and Intermediate Risk MDS with Ring Sideroblasts: First Results of the Lusplus Trial

Blood (2024) 144 (Supplement 1): 3207.

https://doi.org/10.1182/blood-2024-208432

Published: 2024

Journal Articles

Prevalence and Mutational Make-up of Secondary Hematologic Neoplasms in Multiple Myeloma Patients after CAR-T Cell Therapy

Blood (2024) 144 (Supplement 1): 4688.

https://doi.org/10.1182/blood-2024-210233

Published: 2024

Journal Articles

A Phase 1, Open-Label, Dose Escalation and Dose Expansion Study of Cln-049 for the Treatment of Acute Myeloid Leukemia Patients with Measurable Residual Disease

Blood (2024) 144 (Supplement 1): 2883.1.

https://doi.org/10.1182/blood-2024-201478

Published: 2024

Journal Articles

The Differential Impact of Secondary-Type Mutations in a Multinational Cohort of 5311 Intensively Treated Acute Myeloid Leukemia Patients

Jan-Niklas Eckardt, Marius Bill, Konstanze Döhner, Christian Rausch, Klaus H Metzeler, Karsten Spiekermann, Sebastian Stasik, Tim Sauer, Sebastian Scholl, Andreas Hochhaus, Martina Crysandt, Tim H. H. Brummendorf, Utz Krug, Bernhard Wörmann, Hermann Einsele, Wolfgang Hiddemann, Dennis Görlich, Maria Cristina Sauerland, Björn Steffen, Andreas Neubauer, Andreas Burchert, Kerstin Schaefer-Eckart, Wolfgang E. Berdel, Christoph Schliemann, Stefan W. Krause, Mathias Hänel, Maher Hanoun, Martin Kaufmann, Lars Fransecky, Jan Braess, Johannes Schetelig, Jan Moritz Middeke, Lars Bullinger, Michael Heuser, Felicitas R Thol, Hubert Serve, Claudia D Baldus, Uwe Platzbecker, Carsten Mueller-Tidow, Barbora Weinbergerova, Jiri Mayer, Pierre-Yves Dumas, Sarah Bertoli, Eric Delabesse, Christian Récher, Arnaud Pigneux, Tobias Herold, Arnold Ganser, Hartmut Döhner, Martin Bornhäuser, Christian Thiede, Christoph Röllig

Blood (2024) 144 (Supplement 1): 2934.

https://doi.org/10.1182/blood-2024-201945

Published: 2024

Journal Articles

The Differences between Ide-Cel and Cilta-Cel in Relapsed Myeloma at Single Cell Resolution

Blood (2024) 144 (Supplement 1): 1877.

https://doi.org/10.1182/blood-2024-210746

Published: 2024

Journal Articles

Targeting of Various Inflammatory Circuits Does Not Ameliorate Ineffective Hematopoiesis: Results of the Lucas and Canfire Studies Investigating IRAK4 or IL-1β Blockade to Target Anemia in Lower-Risk MDS

Anne Sophie Kubasch, Katharina Zoldan, Michael Cross, Marie Schneider, Jens Przybilla, Dirk Hasenclever, Klaus H Metzeler, Uwe Platzbecker

Blood (2024) 144 (Supplement 1): 3221.

https://doi.org/10.1182/blood-2024-199032

Published: 2024

Journal Articles

Measurable Residual Disease Detection of IDH1 or IDH2 Mutations Post but Not Prior to Allogeneic Hematopoietic Stem Cell Transplantation Show High Prognostic Relevance in Patients with Acute Myeloid Leukemia

Jacob Jendro, Lara Bischof, Jule Ussmann, Tung Pham Thanh, Donata Backhaus, Dominic Brauer, Vladan Vucinic, Carmen Herling, Marco Herling, Georg-Nikolaus Franke, Maximilian Merz, Klaus H Metzeler, Uwe Platzbecker, Sebastian Schwind, Madlen Jentzsch

Blood (2024) 144 (Supplement 1): 4334.

https://doi.org/10.1182/blood-2024-207490

Published: 2024

Journal Articles

The Presence of SH2B3 mutations Identifies a Distinct Subtype of Myelodysplastic Neoplasms

Blood (2024) 144 (Supplement 1): 3214.

https://doi.org/10.1182/blood-2024-194488

Published: 2024

Journal Articles

Genomic Characterization of Acute Myeloid Leukemia with Aberrations of Chromosome 7: A Multinational Cohort of 523 Patients

Blood (2023) 142 (Supplement 1): 63.

https://doi.org/10.1182/blood-2023-185627

Published: 2023

Journal Articles

Machine Learning Provides Individualized Prediction of Outcomes after First Complete Remission in Adult AML Patients - Results from the Harmony Platform

Blood (2023) 142 (Supplement 1): 62.

https://doi.org/10.1182/blood-2023-183029

Published: 2023

Journal Articles

Single Cell Multi-Omic Dissection of Response and Resistance to Chimeric Antigen Receptor T Cells Against BCMA in Relapsed Multiple Myeloma

Blood (2023) 142 (Supplement 1): 453.

https://doi.org/10.1182/blood-2023-187371

Published: 2023

Journal Articles

Apheresis for Production of Chimeric Antigen Receptor (CAR) T Cells in Patients with Multiple Myeloma - Clinical Factors, Cell Composition and T Cell Senescence

Vladan Vucinic, Janine Kirchberg, Mandy Brueckner, Patrick Born, Luise Fischer, Enrica Bach, Nora Grieb, Simone Heyn, Christina Kloetzer, Klaus H Metzeler, Sandra Hoffmann, Carmen Herling, Marco Herling, Georg-Nikolaus Franke, Sebastian Schwind, Song-Yau Wang, Madlen Jentzsch, Uwe Platzbecker, Maximilian Merz

Blood (2023) 142 (Supplement 1): 3521.

https://doi.org/10.1182/blood-2023-182222

Published: 2023

Journal Articles

Cellular Dynamics Following CAR T Cell Therapy Are Associated with Response, Resistance and Cytokine Release Syndrome in Relapsed/Refractory Multiple Myeloma

Blood (2023) 142 (Supplement 1): 1008.

https://doi.org/10.1182/blood-2023-188367

Published: 2023

Journal Articles

Secondary-Type Mutations Do Not Impact the Favorable Outcome of NPM1 -Mutated Acute Myeloid Leukemia Patients - Results from a Large Cohort of Intensively Treated Patients

Blood (2023) 142 (Supplement 1): 721.

https://doi.org/10.1182/blood-2023-186160

Published: 2023

NARROW

Persistent Thrombocytopenia and Neutropenia Are Associated with Increased Mortality in Patients Treated with Anti-BCMA CAR T Cells for Relapsed/Refractory Multiple Myeloma

CT-Based Muscle Quality and Visceral Obesity Prior to Allogeneic Hematopoietic Stem Cell Transplantation Is of Prognostic Relevance in Patients with Acute Myeloid Leukemia

The Prognostic Impact of Myelodysplasia-Related Gene Mutations in Acute Myeloid Leukemia with FLT3 -ITD Mutations

Trial in Progress: A Randomized-Controlled Phase 2 Study Evaluating Venetoclax Plus Azacitidine Versus Intensive Chemotherapy in Adult Patients with Newly Diagnosed, NPM1 -Mutated AML - the SAL/AMLCG Vincent Trial

Prognostic Value of Baseline and Early Response FDG-PET/CT Combined with Cellular Dynamics in Patients with Refractory and Relapsed Mantle Cell Lymphoma (MCL) Undergoing Chimeric Antigen Receptor (CAR)-T Cell Therapy

Serially Transplantable, Genetically Modified Patient Derived Xenograft Models of Acute Myeloid Leukemia Represent Primary Patients' Cells and Enable Reliable and Reproducible Preclinical Therapy Trials

Preliminary Safety and Efficacy of Luspatercept Initiated at Maximum Approved Dose in Patients with Transfusion Dependent Anemia Due to Very Low, Low and Intermediate Risk MDS with Ring Sideroblasts: First Results of the Lusplus Trial

Prevalence and Mutational Make-up of Secondary Hematologic Neoplasms in Multiple Myeloma Patients after CAR-T Cell Therapy

A Phase 1, Open-Label, Dose Escalation and Dose Expansion Study of Cln-049 for the Treatment of Acute Myeloid Leukemia Patients with Measurable Residual Disease

The Differential Impact of Secondary-Type Mutations in a Multinational Cohort of 5311 Intensively Treated Acute Myeloid Leukemia Patients

The Differences between Ide-Cel and Cilta-Cel in Relapsed Myeloma at Single Cell Resolution

Targeting of Various Inflammatory Circuits Does Not Ameliorate Ineffective Hematopoiesis: Results of the Lucas and Canfire Studies Investigating IRAK4 or IL-1β Blockade to Target Anemia in Lower-Risk MDS

Measurable Residual Disease Detection of IDH1 or IDH2 Mutations Post but Not Prior to Allogeneic Hematopoietic Stem Cell Transplantation Show High Prognostic Relevance in Patients with Acute Myeloid Leukemia

The Presence of SH2B3 mutations Identifies a Distinct Subtype of Myelodysplastic Neoplasms

Genomic Characterization of Acute Myeloid Leukemia with Aberrations of Chromosome 7: A Multinational Cohort of 523 Patients

Machine Learning Provides Individualized Prediction of Outcomes after First Complete Remission in Adult AML Patients - Results from the Harmony Platform

Single Cell Multi-Omic Dissection of Response and Resistance to Chimeric Antigen Receptor T Cells Against BCMA in Relapsed Multiple Myeloma

Apheresis for Production of Chimeric Antigen Receptor (CAR) T Cells in Patients with Multiple Myeloma - Clinical Factors, Cell Composition and T Cell Senescence

Cellular Dynamics Following CAR T Cell Therapy Are Associated with Response, Resistance and Cytokine Release Syndrome in Relapsed/Refractory Multiple Myeloma

Secondary-Type Mutations Do Not Impact the Favorable Outcome of NPM1 -Mutated Acute Myeloid Leukemia Patients - Results from a Large Cohort of Intensively Treated Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only